HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety ...

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...